International Clinical Trial: Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07214207) titled 'Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking' on Oct. 1.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).

Primary Sponsor: Ohio State University

Condition: Alcohol Use Disorder

Intervention: Drug: Suvorexant 10 mg

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: December 2025

Target Sample Size: 250

To know more, visit https://clinicaltrials.gov/study/NCT07214207

Published by H...